Galera Therapeutics Files 2024 10-K
Ticker: GRTX · Form: 10-K · Filed: Mar 31, 2025 · CIK: 1563577
Sentiment: neutral
Topics: 10-K, financials, pharmaceuticals
TL;DR
Galera Therapeutics filed its 2024 10-K, detailing financials and operations for the year ending Dec 31, 2024.
AI Summary
Galera Therapeutics, Inc. filed its 2024 10-K on March 31, 2025, reporting on its fiscal year ending December 31, 2024. The company, operating in the pharmaceutical preparations sector, is based in Malvern, PA. Key financial data and operational details for the fiscal year 2024 are presented in this filing.
Why It Matters
This filing provides a comprehensive overview of Galera Therapeutics' financial health and business operations for the past fiscal year, crucial for investors and stakeholders to assess the company's performance and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Galera Therapeutics is subject to significant regulatory, clinical trial, and market risks inherent in drug development and commercialization.
Key Numbers
- 2834 — SIC Code (Standard Industrial Classification for Pharmaceutical Preparations)
- 001-39114 — SEC File Number (Company's SEC filing identifier)
Key Players & Entities
- Galera Therapeutics, Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-03-31 (date) — Filing date
- Malvern, PA (location) — Company headquarters
- Nova Pharmaceuticals Inc. (company) — Mentioned entity
FAQ
What were the primary business activities of Galera Therapeutics during the fiscal year 2024?
The filing indicates Galera Therapeutics operates in the Pharmaceutical Preparations sector (SIC 2834) and details its business activities, including those related to royalty agreements and equity classified items for the period of 2024-01-01 to 2024-12-31.
What is the company's reported fiscal year end?
The company's fiscal year end is December 31, as indicated by the 'FISCAL YEAR END: 1231' and the reporting period '20241231'.
When was this 10-K filing submitted to the SEC?
This 10-K filing was submitted to the SEC on March 31, 2025, as indicated by the accession number and filing date information.
What are some of the financial instruments or accounts mentioned in the filing context?
The filing mentions various financial items including Series A Preferred Stock, Warrants, Additional Paid-In Capital, Retained Earnings, Accumulated Other Comprehensive Income, and Stock Options for periods including 2023 and 2024.
Does the filing mention any specific offering activities?
Yes, the filing references 'ATM Offering' for the periods 2023-01-01 to 2023-12-31 and 2024-01-01 to 2024-12-31, suggesting equity issuance activities.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 31, 2025 regarding Galera Therapeutics, Inc. (GRTX).